Quanterix Corporation (QTRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Quanterix Corporation (QTRX) Healthcare & Pipeline Overview

Quanterix Corporation is a life sciences company specializing in digital immunoassay platforms for precision health. Their Simoa technology offers highly sensitive protein detection, serving academic, governmental, pharmaceutical, and biotech sectors. With a focus on neurology, oncology, and cardiology, Quanterix aims to improve diagnostics and research through advanced immunoassay solutions.

What Is the Investment Thesis for QTRX?

The company's focus on ultra-sensitive protein detection positions it at the forefront of precision health, addressing critical needs in neurology, oncology, and cardiology. Key value drivers include the increasing adoption of its HD-X, SR-X, and SP-X platforms, as well as the expansion of its assay menu and contract research services. Growth catalysts include strategic partnerships with pharmaceutical and biotechnology companies, expansion into new geographic markets, and continued innovation in Simoa technology. However, potential risks include competition from established players in the immunoassay market, regulatory hurdles, and the need for continued investment in research and development to maintain its technological edge. With a market capitalization of $118M and a gross margin of 44.1%, Quanterix demonstrates potential for growth, but its negative profit margin of -71.9% highlights the need for improved operational efficiency and cost management.

Based on FMP financials and quantitative analysis

QTRX Key Highlights

Market capitalization of $118M reflects investor valuation of Quanterix's future growth potential in the precision health market.

• Gross margin of 44.1% indicates the company's ability to generate revenue efficiently from its products and services.
• Operating in the neurology, oncology, cardiology, infectious diseases, and inflammation areas, Quanterix has diversified its revenue streams across multiple high-growth therapeutic areas.
• Quanterix's Simoa technology offers ultra-sensitive protein detection, providing a competitive edge in the diagnostics and life science research markets.
• The company serves a global customer base, including academic, governmental, pharmaceutical, and biotech sectors, through a direct sales force and distributors.

Who Are QTRX's Competitors?

QTRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are QTRX's Key Strengths?

Proprietary Simoa technology enabling ultra-sensitive protein detection.

• Diverse product portfolio including instruments, assays, and services.
• Established customer base in academic, governmental, and pharmaceutical sectors.
• Expertise in immunoassay development and commercialization.

What Are QTRX's Weaknesses?

Negative profit margin indicating operational inefficiencies.

• High reliance on research and development for innovation.
• Limited market share compared to established players in the immunoassay market.
• Potential regulatory hurdles for new diagnostic products.

What Could Drive QTRX Stock Higher?

Expansion of the assay menu to include new biomarkers for neurology and oncology.

• Strategic partnerships with pharmaceutical companies to develop companion diagnostics.
• Continued innovation in Simoa technology to improve sensitivity and throughput.
• Geographic expansion into emerging markets in Asia Pacific and Latin America.

What Are the Key Risks for QTRX?

Financial-distress signal — its Altman Z-Score of -2.32 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-43.6%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Competition from established players in the immunoassay market.
• Regulatory hurdles for new diagnostic products.
• Reliance on research and development for innovation.
• Economic downturn affecting research funding and healthcare expenditure.

What Are the Growth Opportunities for QTRX?

• Expansion of Assay Menu: Quanterix has the opportunity to expand its assay menu to cover a broader range of biomarkers and therapeutic areas. By developing and commercializing new assays, Quanterix can increase its revenue streams and attract new customers. Timeline: Ongoing.
• Strategic Partnerships: Quanterix can leverage strategic partnerships with pharmaceutical and biotechnology companies to accelerate the adoption of its Simoa technology and expand its market reach. Collaborations with industry leaders can provide access to new markets, technologies, and funding opportunities. The market for strategic partnerships in the life sciences sector is highly competitive, but Quanterix's innovative technology and strong scientific reputation position it to attract valuable collaborations. Timeline: Ongoing.
• Geographic Expansion: Quanterix has the opportunity to expand its geographic presence beyond North America, Europe, the Middle East, Africa, and the Asia Pacific regions. Emerging markets such as China and India offer significant growth potential, driven by increasing healthcare expenditure and rising demand for advanced diagnostics. By establishing a local presence in these markets, Quanterix can tap into new customer segments and increase its global market share. Timeline: Ongoing.
• Innovation in Simoa Technology: Quanterix can continue to innovate in Simoa technology to maintain its competitive edge and address emerging needs in the diagnostics and life science research markets. The market for innovative diagnostic technologies is highly dynamic, with new solutions constantly being developed and commercialized. By investing in research and development, Quanterix can develop new Simoa-based platforms and assays that offer improved sensitivity, specificity, and throughput. Timeline: Ongoing.
• Contract Research Services: Quanterix has the opportunity to expand its contract research services, providing sample testing, homebrew assay development, and custom assay development to pharmaceutical, biotechnology, and academic clients. The market for contract research services is projected to grow significantly, driven by the increasing demand for outsourced research and development. By leveraging its expertise in Simoa technology and its state-of-the-art facilities, Quanterix can attract new clients and increase its revenue streams. Timeline: Ongoing.

What Are QTRX's Competitive Advantages?

• Proprietary Simoa Technology: Provides ultra-sensitive protein detection capabilities.
• Established Customer Base: Strong relationships with leading research institutions and pharmaceutical companies.
• Comprehensive Product Portfolio: Offers a range of instruments, assays, and services to meet diverse customer needs.
• Expertise in Immunoassay Development: Deep scientific knowledge and experience in developing and commercializing immunoassay solutions.

What Does QTRX Do?

Quanterix Corporation, originally Digital Genomics, Inc. before rebranding in 2007, was founded with the mission of revolutionizing diagnostics and life science research through ultra-sensitive protein detection. The company develops and commercializes digital immunoassay platforms based on its proprietary Simoa (Single Molecule Array) technology. This technology enables the precise and early detection of biomarkers, facilitating advancements in precision health. Quanterix's flagship products include the HD-X, SR-X, and SP-X instruments, each designed to cater to different research and diagnostic needs. The HD-X is a fully automated platform for high-throughput multiplex protein detection, while the SR-X allows researchers to apply Simoa technology in diverse applications, including direct nucleic acid detection. The SP-X instrument utilizes Simoa planar array technology for multiplex chemiluminescent immunoassays. In addition to instruments, Quanterix offers a comprehensive range of assay kits and consumables, including reagents, to support its platforms. The company also provides contract research services, such as sample testing, homebrew assay development, and custom assay development, catering to the specific needs of its clients. Quanterix primarily focuses on key therapeutic areas, including neurology, oncology, cardiology, infectious diseases, and inflammation. The company serves a global customer base, including laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies, through a direct sales force, support organizations, and distributors or sales agents. Headquartered in Billerica, Massachusetts, Quanterix continues to innovate and expand its offerings to drive advancements in precision health and improve patient outcomes.

What Products and Services Does QTRX Offer?

• Develops and markets digital immunoassay platforms.
• Offers the HD-X instrument for automated multiplex protein detection.
• Provides the SR-X instrument for Simoa detection technology applications.
• Offers the SP-X instrument based on Simoa planar array technology.
• Sells assay kits and consumables, including reagents.
• Provides contract research services, including sample testing.
• Offers homebrew assay development and custom development services.

How Does QTRX Make Money?

• Sells digital immunoassay platforms (HD-X, SR-X, SP-X) to research and diagnostic labs.
• Generates revenue from the sale of assay kits and consumables required for platform operation.
• Provides contract research services, including sample testing and assay development, for a fee.
• Utilizes a direct sales force and distributors to reach customers in North America, Europe, and Asia Pacific.

What Industry Does QTRX Operate In?

Quanterix Corporation operates within the medical devices industry, a segment of the broader healthcare sector. The industry is characterized by rapid technological advancements, increasing demand for precision diagnostics, and growing investments in research and development. Quanterix's Simoa technology positions it to capitalize on the growing demand for ultra-sensitive protein detection in areas such as neurology, oncology, and cardiology. The competitive landscape includes established players in the immunoassay market, as well as emerging companies developing innovative diagnostic solutions.

Who Are QTRX's Key Customers?

• Academic research institutions
• Governmental research institutions
• Pharmaceutical companies
• Biotechnology companies
• Contract research organizations (CROs)

Over the past six months, Quanterix Corporation insiders filed 95 SEC Form 4 transactions — 57 sales and 38 purchases. On net that is roughly 252K shares acquired (about $325K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Quanterix Corporation

Revenue for Quanterix Corporation came in at $32.9M during Q2 FY2026, a 9.6% contraction versus the preceding quarter. The company recorded a net loss of $48.9M, with diluted EPS of $-1.04. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, QTRX averaged $-0.66 in diluted EPS.

QTRX Valuation & Market Position

With a $118M market cap, Quanterix Corporation sits in the micro-cap segment of the market. Analyst price targets span from $3.00 to $3.00, with a consensus of $3.00. At the current price of $2.50, that implies approximately 20% upside potential. Relative to its peer group, QTRX's quantitative score of 17/100 is below the peer average of 50/100.

Return on equity for Quanterix Corporation stands at -43.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -38.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -59.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -99.3%, the inverse of the P/E and a quick read on earnings relative to price.

Quanterix Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.32 places it in the distress zone, a signal of elevated financial risk.

Quanterix Corporation has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 63.0% below estimates on average.

Company Profile

Quanterix Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Billerica, US. The company is led by CEO Everett V. Cunningham. QTRX has traded publicly since 2017.

QTRX Financials

QTRX Latest News

QTRX Analyst Consensus

QTRX MoonshotScore

What Investors Ask About Quanterix Corporation (QTRX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources